13F Holdings
中文EN

INSM INSMED Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1104506 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY240.0%
TTM net income YoY48.8%
TTM EPS YoY54.6%
Revenue 3-yr CAGR75.6%
Net income 3-yr CAGR—

Margins

Gross margin84.4%
Operating margin-37.1%
Net margin-39.9%
FCF margin-41.3%
EBITDA margin-36.3%

Returns

ROE-72.5%
ROA-26.4%
ROIC (approx.)-43.8%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets67.4%
Debt / equity0.76x
Current ratio2.86x
Interest coverage-6.93x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$606.42M$363.71M$305.21M$245.36M$188.46M
Cost of revenue$122.94M$85.74M$65.57M$55.13M$44.15M
Gross profit$483.49M$277.96M$239.63M$190.23M$144.31M
R&D expense$771.09M$598.37M$571.01M$397.52M$272.74M
SG&A expense$701.17M$461.12M$344.50M$265.78M$234.27M
Operating income-$1.25B-$878.25M-$709.63M-$457.32M-$375.09M
Interest expense$83.80M$84.91M$81.69M$26.45M$40.47M
Pretax income-$1.27B-$910.07M-$747.01M-$480.15M-$436.41M
Income tax$5.03M$3.71M$2.56M$1.38M-$1.76M
Net income-$1.28B-$913.77M-$749.57M-$481.53M-$434.65M
EBITDA-$1.24B-$872.29M-$704.10M-$452.04M-$365.99M
EPS (basic)-6.42-5.57-5.34-3.91-3.88
EPS (diluted)-6.42-5.57-5.34-3.91-3.88
Weighted avg. shares (diluted)199.01M164.04M140.43M123.03M112.11M
Balance sheet
Cash & equivalents$510.44M$555.03M$482.37M$1.07B$716.78M
Short-term investments$919.60M$878.80M$298.07M$74.24M$0
Receivables$140.86M$52.01M$41.19M$29.71M$24.35M
Inventory$132.07M$98.58M$83.25M$69.92M$67.01M
Current assets$1.79B$1.62B$929.06M$1.27B$837.04M
PP&E, net$102.94M$80.05M$65.38M$56.49M$52.95M
Goodwill$136.11M$136.11M$136.11M$136.11M$136.11M
Intangibles$97.65M$58.65M$63.70M$68.76M$73.81M
Total assets$2.26B$2.03B$1.33B$1.66B$1.24B
Current liabilities$468.87M$297.53M$225.63M$190.24M$135.17M
Short-term debt$0—$0——
Long-term debt$540.96M$1.10B$1.16B$1.13B$566.59M
Total debt$540.96M$1.10B$1.16B$1.13B$566.59M
Total liabilities$1.53B$1.74B$1.66B$1.57B$833.04M
Shareholders' equity$738.98M$285.38M-$331.92M$87.95M$410.47M
Net debt$30.52M$548.35M$672.94M$51.21M-$150.19M
Shares outstanding214.26M179.38M147.98M135.65M118.74M
Cash flow statement
Operating cash flow-$935.01M-$683.88M-$536.25M-$400.44M-$363.30M
Capital expenditure$32.56M$21.92M$13.29M$9.88M$7.29M
Free cash flow-$967.58M-$705.80M-$549.53M-$410.32M-$370.59M
Investing cash flow-$64.58M-$583.17M-$223.60M-$34.58M-$64.28M
Financing cash flow$954.07M$1.34B$168.44M$793.27M$612.55M
Depreciation & amortization$10.45M$5.96M$5.53M$5.28M$9.10M
Stock-based compensation$152.71M$96.83M$74.78M$57.69M$46.02M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.